BastRCFeenyMLazarusHNadlerLMColvinRBKnappRC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest1981; 68: 1331–7
2.
ThorlanderBLindgrenATaubeAStensonS. Immunohistochemical detection of CA 125 and carcinoembryonic antigen in ovarian tumours in relation to corresponding preoperative serum levels. Int J Gynecol Cancer1992; 2: 263–70
3.
TuxenMKSoletormostGDombernowskyP. Tumour markers in the management of patients with ovarian cancer. Cancer Treat Rev1995; 21: 215–45
4.
XuF-JYuY-HDalyLDeSombreKAnselminoLHassMH. OCX1 Radioimmunoassay complements CA 125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures. J Clin Oncol1983; 11: 1506–10
5.
WardBGMcGuckinMARammLECoglanLESandersonBTripconyB. The managment of ovarian carcinoma is improved by the use of cancer associated serum antigen (CASA) and CA 125 assays. Cancer1993; 71: 430–8
6.
SundstromBEStigbrandTI. Cytokeratins and tissue polypeptide antigen. Int J Biol Mark1994; 9: 102–8
7.
JacobsIStabileIBridgesJFayTLowwerA. Prevalence screening for ovarian cancer in post-menopausal women by CA 125 measurement and ultrasonography. BMJ1993; 306: 1030–4
8.
WoolasRPXuFJJacobsIJYuYHDalyLBerchuckA. Elevation of multiple serum markers in patients with stage I ovarian cancer. J Natl Cancer Inst1993; 85: 1748
9.
Van der BurgMELLammesFBVerweijJ. Review CA 125 in ovarian cancer. Neth J Med1992; 40: 36–51
10.
McGuckinMARammLEJoyGJFreeGJWardKEWardBG. Preoperative discrimination between ovarian carcinoma, non-ovarian gynecological malignancy and benign adnexal masses using serum levels of CA 125 and the polymorphic epithelial mucin antigens CASA, OSA, and MSA. Int J Gynecol Cancer1992; 2: 119–28
11.
MogensenOMogensenBJakobsenA. Tumour-associated trypsin inhibitor and cancer antigen 125 in pelvic masses. Gynecol Oncol1990; 38: 170–4
12.
JacobsIOranDFairbanksJTurnerJFrostCGrudzinkasJG. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynecol1990; 97: 922–9
13.
CruickshankDJFullertonWTKlopperA. The clinical significance of preoperative serum CA 125 in ovarian cancer. Br J Obstet Gynaecol1987; 94: 692–5
14.
MobusVKreienbergRCrombachGWurzHCaffierHKaesemannH. Evaluation of CA 125 as a prognostic and predictive factor in ovarian cancer. J Tumour Mark Oncol1988; 3: 251–8
15.
TholanderBTaubeALindgrenASjobergOStendahlUTamsenL. Pretreatment serum levels of CA 125, Carcinoembryonic antigen, tissue polypeptide antigen, and placental alkaline phosphatase in patients with ovarian carcinoma: Influence of histological type, grade of differentiation, and clinical stage of disease. Gynecol Oncol1990; 39: 26–33
16.
ZanaboniF. Vergadoro F, Presti M. Tumour antigen CA 125 as a tumour marker of ovarian epithelial carcinoma. Gynecol Oncol1987; 28: 61–7
17.
ParkerDPatelKAlfredEJHarnden-MayorPNaylorB. CA 125 and survival in ovarian cancer. J R Soc Med1988; 82: 22
18.
LavinPTKnappRCMalkasanGWhitneyCWBerekJCBastRC. CA 125 for the monitoring of ovarian carcinoma during primary therapy. Obstet Gynecol1987; 69: 223–7
19.
MorgensenO. Prognostic value of CA 125 in advanced ovarian cancer. Gynecol Oncol1992; 44: 207–12
20.
Van der BurgMELLammesFBvan PuttenWLJStoterG. Ovarian cancer: The prognostic value of the serum half-life of CA 125 during induction chemotherapy. Gynecol Oncol1988; 30: 307–12
21.
RustinGJSGenningsJNNelstropAECavarrubiasHLambertHEBagshaweKD. Use of CA 125 to predict survival of patients with ovarian carcinoma. J Clin Oncol1989; 7: 1667–71
22.
FayersPMRustinGJSWoodRNelstropALeonardRCFWilkinsonP. The prognostic value of serum CA 125 in patients with advanced ovarian carcinoma: An analysis of 573 patients by the Medical Research Council Working Party on gynaecological cancer. Int J Gynecol Cancer1993; 3: 285–92
23.
RustinGJSNelstropAEMcCleanP. Defining response of ovarian carcinoma in initial chemotherapy according to serum CA 125. J Clin Oncol1996 (in press)
24.
RustinGJSVan der BurgMELBerekJS. Tumour markers. Ann Oncol1993; 4: S71–S77
25.
Van der BurgMELLammesFBVerweijJ. The role of CA 125 in the early diagnosis of progressive disease in ovarian cancer. Ann Oncol1990; 1: 301–2
26.
RustinGJSNelstropAStilwellJLambertHE. Savings obtained by CA 125 measurements during therapy for ovarian carcinoma. Eur J Cancer1992; 28: 79–82
27.
KrebsHBGoplerudDRKilpatrickSJMyersSJHuntMBHuntA. The role of CA 125 as a tumour marker in ovarian carcinoma. Obstet Gynecol1986; 67: 473–7
28.
BastRKlugTLJohnESJenisonENiloffJMLazarusH. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med1983; 309: 883–7
29.
NiloffJMKnappRCLavinPTMalkasianGDBerekJSMortelR. The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer. Am J Obstet Gynecol1986; 155: 56–60
30.
RustinGJSNelstropAETuxenMJLambertHE. Defining progression of ovarian carcinoma during follow-up according to CA 125: A North Thames group study. Ann Oncol1996 (in press)
31.
PanzaNPacilioGCampanellaLPelusoGBattistaCAmorielloA. Cancer antigen 125, tissue polypeptide antigen, carcinoembryonic antigen, and beta-chain human chorionic gonadotrophin as serum markers of epithelial ovarian carcinoma. Cancer1988; 61: 76–83
32.
FiorettiPGaducciAFerdeghiniMPronteraCMalagninoGFacchiniV. Concomitant determination of different serum tumour markers in epithelial ovarian cancer relevance for monitoring the response to chemotherapy and follow-up patients. Gynecol Oncol1992; 44: 155–60
33.
BerekJSKnappRCMalkasianGDLavinPYWhitneyCNiloffJM. CA 125 serum levels correlated with second-look operations among ovarian cancer patients. Obstet Gynecol1986; 67: 685–9
34.
MakarAPKristensenGBBormerOPTropeCG. CA 125 measured before second-look laparotomy is an independent prognostic factor for survival in patients with epithelial ovarian cancer. Gynecol Oncol1992; 45: 323–8
35.
Van der BurgMELvan LentMBuyseMKobierskaAColomboNFavalliG. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med1995; 332: 629–34
